Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its...

SIBN : 19.70 (+3.36%)
NVCR : 80.09 (+2.89%)
NERV : 7.45 (-1.32%)
XENT : 21.52 (+0.19%)
AMRS : 3.26 (-6.72%)
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a...

NVCR : 80.09 (+2.89%)
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference

Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure's Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr. Doyle's presentation...

NVCR : 80.09 (+2.89%)
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology

Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO)...

NVCR : 80.09 (+2.89%)
NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 80.09 (+2.89%)
Novocure Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Novocure Ltd. (NASDAQ: ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 31, 2019 at 8:00 AM Eastern...

NVCR : 80.09 (+2.89%)
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

--First quarter ever of positive net income with $0.02 in earnings per share

NVCR : 80.09 (+2.89%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 47.16 (-0.31%)
IWP : 150.50 (+0.14%)
PODD : 175.65 (+1.37%)
FCN : 111.63 (+1.74%)
NVCR : 80.09 (+2.89%)
IJK : 234.05 (-0.30%)
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

--NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years

NVCR : 80.09 (+2.89%)
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

--NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years

NVCR : 80.09 (+2.89%)
NVE Schedules Conference Call on Second-Quarter Results

NVE Corporation (Nasdaq: NVEC) announced that it plans to release its financial results for the quarter and six months ended September 30, 2019 on Wednesday, October 23, 2019 after the close of the Nasdaq...

NVCR : 80.09 (+2.89%)
NVEC : 67.10 (+0.04%)
Novocure to Report Third Quarter 2019 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will...

NVCR : 80.09 (+2.89%)
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting

--Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and the first presentation of in vitro data combining treatment with Tumor...

NVCR : 80.09 (+2.89%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 47.16 (-0.31%)
IWP : 150.50 (+0.14%)
NVCR : 80.09 (+2.89%)
AYX : 95.53 (+0.95%)
ROKU : 132.49 (-5.07%)
IJK : 234.05 (-0.30%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 47.16 (-0.31%)
IWP : 150.50 (+0.14%)
PODD : 175.65 (+1.37%)
FCN : 111.63 (+1.74%)
NVCR : 80.09 (+2.89%)
IJK : 234.05 (-0.30%)
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune(R) in China

Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called...

NVCR : 80.09 (+2.89%)
ZLAB : 43.06 (+0.07%)
Novocure to Participate in Three Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that it will participate in three upcoming investor conferences.

NVCR : 80.09 (+2.89%)
NovoCure Limited (NVCR) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).

NVCR : 80.09 (+2.89%)
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 85.71% and 6.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 80.09 (+2.89%)
Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update

--The NovoTTF-100L(TM) System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocure's first FDA-approved torso indication

NVCR : 80.09 (+2.89%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.68 , AIZ -0.29 , SBAC +7.43 , SO +0.05 , WELL -0.46
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar